Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 3:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,787 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced or Metastatic NSCLC
Interventions
Datopotamab deruxtecan, KEYTRUDA®, Carboplatin, Cisplatin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 5 more
Conditions
Ovarian Neoplasms
Interventions
9-aminocamptothecin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Small Cell Lung Carcinoma
Interventions
figitumumab, Cisplatin (Or Carboplatin), Etoposide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
34
States / cities
Washington D.C., District of Columbia • Marrero, Louisiana • Metairie, Louisiana + 28 more
Conditions
Stage IIIA Non-small Cell Lung Cancer
Interventions
proton beam radiation therapy, cisplatin, etoposide, therapeutic conventional surgery
Radiation · Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Carcinoma, Squamous, Head and Neck Cancer, Oral Cancer, Laryngeal Cancer, Pharyngeal Cancer
Interventions
Bortezomib (Velcade, PS-341), Cetuximab, Cisplatin, Radiation Therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Interventions
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
8
States / cities
Chandler, Arizona • Tucson, Arizona • Cerritos, California + 4 more
Conditions
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
bryostatin 1, cisplatin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Duarte, California
Conditions
Limited Stage Small Cell Lung Cancer
Interventions
tirapazamine, cisplatin, etoposide, radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Lung Cancer
Interventions
Pembrolizumab, Epacadostat, Platinum-based chemotherapy, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
21
States / cities
Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 18 more
Conditions
Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer, Melanoma, Stage IV Head and Neck Cancer
Interventions
Cisplatin, Docetaxel, Bevacizumab, Erlotinib, Radiotherapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
Interventions
Bintrafusp Alfa, Pemetrexed, Carboplatin, Cisplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
alvocidib, cisplatin, paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
New York, New York
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, cisplatin, cyclophosphamide, etoposide, methotrexate, vincristine sulfate, adjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
10 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
2
States / cities
Los Angeles, California • Danville, Pennsylvania
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, ifosfamide, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma
Interventions
Interim/Maintenance Dexamethasone, Induction/Consolidation Dexamethasone, Induction/Consolidation Cisplatin, Induction/Consolidation Adriamycin, InductionConsolidation Cyclophosphamide, Induction/Consolidation Etoposide, Induction Pegfilgrastim, Transplant 1 Dexamethasone, Transplant 1 Cisplatin, Transplant 1 Adriamycin, Transplant 1 Cyclophosphamide, Transplant 1 Etoposide, Transplant 1 Melphalan, Transplant 1 and 2 Pegfilgrastim, Autologous Peripheral Blood Stem Cell Transplant (ASCT), Transplant 2 Carmustine, Transplant 2 Etoposide, Transplant 2 Cytarabine, Transplant 2 Melphalan, Transplant 2 Dexamethasone, Transplant 1 and 2 Bortezomib, Transplant 1 and 2 Thalidomide
Drug · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Breast Cancer
Interventions
filgrastim, CAF regimen, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, fluorouracil, ifosfamide, melphalan, paclitaxel, thiotepa, peripheral blood stem cell transplantation, samarium Sm 153 lexidronam pentasodium
Biological · Drug · Procedure + 1 more
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Shreveport, Louisiana
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Nivolumab, Ipilimumab, Pemetrexed, Cisplatin, Carboplatin
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
18
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 12 more
Conditions
Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
Interventions
Cisplatin, Panitumumab, Docetaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
82
States / cities
Tucson, Arizona • Jonesboro, Arkansas • Duarte, California + 67 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
7-hydroxystaurosporine, cisplatin
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
4
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 1 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Savolitinib, Osimertinib, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Orlando, Florida • Honolulu, Hawaii • New Brunswick, New Jersey + 2 more
Conditions
Non Small Cell Lung Cancer
Interventions
IPH5201 + durvalumab + standard chemotherapy
Drug
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
St. Petersburg, Florida • Tampa, Florida • Chicago, Illinois + 3 more
Conditions
Cervical Cancer
Interventions
cetuximab, cisplatin
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
18
States / cities
Burbank, California • Los Angeles, California • Savannah, Georgia + 14 more
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
cisplatin, paclitaxel, pemetrexed disodium, biologic sample preservation procedure
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Scottsdale, Arizona • Tucson, Arizona
Conditions
Lymphoma
Interventions
cisplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, syngeneic bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Temple University
Other
Eligibility
15 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania